Literature DB >> 29258384

Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer.

Elke Van Daele1, Vincenzo Scuderi1, Eva Pape1, Dirk Van de Putte1, Oswald Varin1, Yves Van Nieuwenhove1, Wim Ceelen1, Roberto Troisi1, Piet Pattyn1.   

Abstract

BACKGROUND AND OBJECTIVES: Esophageal cancer (EC) remains an aggressive disease with a poor survival. Management of metastatic EC is limited to palliative chemotherapy (CT). Scientific contributions regarding the role of surgery are scarce and controversial. We analysed outcome of surgically treated metastatic EC patients.
METHODS: We retrospectively identified surgically treated metastatic EC patients from our esophagectomy database. The aim of this study was to evaluate surgical complications, pathological response, oncological outcome and mean survival of these aggressively treated stage IV cancer patients.
RESULTS: Twelve stage IV patients with disease presentation limited to outfield lymph node (LN) and/or liver metastasis were treated with an aggressive multimodality treatment including surgery. Mean age was 58 years (75% male, 75% Adenocarcinomas). Median postoperative hospital stay was 15 d. Radiological anastomotic leakage occurred in one patient. In hospital, mortality was nil. Complete resection was achieved in all but one. Metastatic recurrence occurred in 64% of R0 resected patients. At date of censoring, after a median follow-up of 22 months, 50% of the surgical resected patients are still alive and 33% are free of disease recurrence. Kaplan-Meier curves show a possibility to long-term survival after aggressive multimodality therapy including surgery.
CONCLUSIONS: In selected metastatic EC patients, multimodality treatment including surgery has an acceptable surgical outcome with a potentially long-term survival.

Entities:  

Keywords:  Stage IV esophageal cancer; esophagectomy; metastases

Mesh:

Year:  2017        PMID: 29258384     DOI: 10.1080/00015458.2017.1411557

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  6 in total

1.  Image-guided interstitial high-dose-rate brachytherapy in the treatment of metastatic esophageal squamous cell carcinoma.

Authors:  Jazan Omari; Constanze Heinze; Antje Wilck; Peter Hass; Max Seidensticker; Robert Damm; Katharina Fischbach; Jens Ricke; Maciej Pech; Maciej Powerski
Journal:  J Contemp Brachytherapy       Date:  2018-10-23

2.  Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer.

Authors:  Jing Xu; Donghui Lu; Li Zhang; Jian Li; Guoping Sun
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

Review 3.  Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments.

Authors:  Fabio Procopio; Salvatore Marano; Damiano Gentile; Anna Da Roit; Silvia Basato; Pietro Riva; Ferdinando De Vita; Guido Torzilli; Carlo Castoro
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

4.  The Effect of the Appropriate Timing of Radiotherapy on Survival Benefit in Patients with Metastatic Esophageal Cancer Who Have Undergone Resection of Primary Site: A SEER Database Analysis.

Authors:  Bingzhe Qiu; Yong Zhou; Ming Lou; Ke Zhang; Jiawei Lu; Jichun Tong
Journal:  J Oncol       Date:  2022-03-16       Impact factor: 4.375

Review 5.  Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence.

Authors:  Andreas R R Weiss; Noel E Donlon; Hans J Schlitt; Christina Hackl
Journal:  Langenbecks Arch Surg       Date:  2021-12-03       Impact factor: 2.895

Review 6.  Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review.

Authors:  Thomas Bardol; Lorenzo Ferre; Safa Aouinti; Marie Dupuy; Eric Assenat; Jean-Michel Fabre; Marie-Christine Picot; Regis Souche
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.